Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma.

ABSTRACT:

Background

The current standard of care for locally advanced esophageal and gastroesophageal junction (GEJ) cancers includes neoadjuvant chemoradiotherapy or perioperative chemotherapy with surgical resection; however, disease-free survival in these patients remains poor. Immune checkpoint inhibitors (ICIs) are approved for adjuvant treatment of locally advanced esophageal and GEJ cancers, but their benefit in the perioperative and neoadjuvant settings remains under investigation.

Methods

We used the PubMed online database to conduct a literature search to identify studies that investigated immunotherapy for locally advanced esophageal and GEJ carcinoma. A review of ClinicalTrials.gov yielded a list of ongoing trials.

Results

Adjuvant nivolumab for residual disease af

SUBMITTER: Fick CN 

PROVIDER: S-EPMC11194153 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature